{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:28:46Z","timestamp":1786786126488,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Project of Sun Yat-sen Memorial Hospital","award":["9400023013"],"award-info":[{"award-number":["9400023013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07080-3","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:05:16Z","timestamp":1780085116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification and validation of a prognostic risk-scoring model in drug-resistant ALL and evaluation of immune micro-environment"],"prefix":"10.1007","volume":"105","author":[{"given":"Yun-yao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-xi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-wei","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-pei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"9","key":"7080_CR1","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","volume":"35","author":"I Iacobucci","year":"2017","unstructured":"Iacobucci I, Mullighan CG (2017) Genetic Basis of Acute Lymphoblastic Leukemia. J Clin Oncol 35(9):975\u2013983. https:\/\/doi.org\/10.1200\/JCO.2016.70.7836","journal-title":"J Clin Oncol"},{"issue":"10230","key":"7080_CR2","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M (2020) Acute lymphoblastic leukemia. Lancet 395(10230):1146\u20131162. https:\/\/doi.org\/10.1016\/S0140-6736(19)33018-1","journal-title":"Lancet"},{"issue":"27","key":"7080_CR3","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP et al (2015) Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol 33(27):2938\u20132948. https:\/\/doi.org\/10.1200\/JCO.2014.59.1636","journal-title":"J Clin Oncol"},{"issue":"4","key":"7080_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1590\/s1516-31802004000400007","volume":"122","author":"ET Valera","year":"2004","unstructured":"Valera ET, Scrideli CA, Queiroz RG, Mori BM, Tone LG (2004) Multiple chemotherapy resistance protein (MDR-1), multichemotherapy resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J 122(4):166\u2013171. https:\/\/doi.org\/10.1590\/s1516-31802004000400007","journal-title":"Sao Paulo Med J"},{"issue":"2","key":"7080_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.20517\/cdr.2019.11","volume":"2","author":"LK Meyer","year":"2019","unstructured":"Meyer LK, Hermiston ML (2019) The epigenome in pediatric acute lymphoblastic leukemia: chemotherapy resistance and therapeutic opportunities. Cancer Drug Resist 2(2):313\u2013325. Published 2019 Jun 19. https:\/\/doi.org\/10.20517\/cdr.2019.11","journal-title":"Cancer Drug Resist"},{"issue":"6","key":"7080_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ (2019) Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 16(6):372\u2013385. https:\/\/doi.org\/10.1038\/s41571-019-0184-6","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"7080_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","volume":"204","author":"EM Leslie","year":"2005","unstructured":"Leslie EM, Deeley RG, Cole SP (2005) Multichemotherapy resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204(3):216\u2013237. https:\/\/doi.org\/10.1016\/j.taap.2004.10.012","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"7080_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/172460080001500101","volume":"15","author":"VM De Benedetti","year":"2000","unstructured":"De Benedetti VM, Biglia N, Sismondi P, De Bortoli M (2000) DNA chips: the future of biomarkers. Int J Biol Markers 15(1):1\u20139. https:\/\/doi.org\/10.1177\/172460080001500101","journal-title":"Int J Biol Markers"},{"issue":"4","key":"7080_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","volume":"31","author":"G Ghiaur","year":"2017","unstructured":"Ghiaur G, Levis M (2017) Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow microenvironment. Hematol Oncol Clin North Am 31(4):681\u2013692. https:\/\/doi.org\/10.1016\/j.hoc.2017.04.005","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"7080_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00262-017-2058-z","volume":"67","author":"F Petitprez","year":"2018","unstructured":"Petitprez F, Vano YA, Becht E et al (2018) Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunol Immunother 67(6):981\u2013988. https:\/\/doi.org\/10.1007\/s00262-017-2058-z","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"7080_CR11","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng MW, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res 75(11):2139\u20132145. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0255","journal-title":"Cancer Res"},{"key":"7080_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH (2020) CD40 Agonist Antibodies in Cancer Immunotherapy. Annu Rev Med 71:47\u201358. https:\/\/doi.org\/10.1146\/annurev-med-062518-045435","journal-title":"Annu Rev Med"},{"issue":"17","key":"7080_CR13","doi-asserted-by":"publisher","first-page":"10095","DOI":"10.3390\/ijms231710095","volume":"23","author":"P Nasri Nasrabadi","year":"2022","unstructured":"Nasri Nasrabadi P, Martin D, Gharib E, Robichaud GA (2022) The Pleiotropy of PAX5 Gene Products and Function. Int J Mol Sci. 23(17):10095. Published 2022 Sep 3. https:\/\/doi.org\/10.3390\/ijms231710095","journal-title":"Int J Mol Sci"},{"issue":"50","key":"7080_CR14","doi-asserted-by":"publisher","first-page":"eadd6403","DOI":"10.1126\/sciadv.add6403","volume":"8","author":"Y Li","year":"2022","unstructured":"Li Y, Moriyama T, Yoshimura S et al (2022) PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci Adv 8(50):eadd6403. https:\/\/doi.org\/10.1126\/sciadv.add6403","journal-title":"Sci Adv"},{"issue":"7","key":"7080_CR15","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41375-025-02626-2","volume":"39","author":"F Auer","year":"2025","unstructured":"Auer F, Morcos MNF, Sipola M et al (2025) Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo. Leukemia 39(7):1607\u20131626. https:\/\/doi.org\/10.1038\/s41375-025-02626-2","journal-title":"Leukemia"},{"issue":"21","key":"7080_CR16","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1158\/1078-0432.CCR-15-1945","volume":"22","author":"K Munakata","year":"2016","unstructured":"Munakata K, Uemura M, Tanaka S et al (2016) Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity. Clin Cancer Res 22(21):5277\u20135286. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1945","journal-title":"Clin Cancer Res"},{"issue":"7","key":"7080_CR17","doi-asserted-by":"publisher","first-page":"5941562","DOI":"10.1155\/2022\/5941562","volume":"23","author":"Y Wang","year":"2022","unstructured":"Wang Y, Luo S, Wang Y et al (2022) EID3 Promotes cancer stem cell-like phenotypes in osteosarcoma through the activation of PI3K-AKT signaling pathway. Oxid Med Cell Longev 23(7):5941562. Published 2022 Aug 28. https:\/\/doi.org\/10.1155\/2022\/5941562","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"7080_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.canlet.2011.05.005","volume":"308","author":"Q Li","year":"2011","unstructured":"Li Q, Wang L, Tan W et al (2011) Identification of C1qTNF-related protein 4 as a potential cytokine that stimulates the STAT3 and NF-\u03baB pathways and promotes cell survival in human cancer cells. Cancer Lett 308(2):203\u2013214. https:\/\/doi.org\/10.1016\/j.canlet.2011.05.005","journal-title":"Cancer Lett"},{"key":"7080_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1062225","author":"M Khan","year":"2022","unstructured":"Khan M, Ai M, Du K et al (2022) Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective. Front Immunol. 13:1062225. Published 2022 Dec 20. https:\/\/doi.org\/10.3389\/fimmu.2022.1062225","journal-title":"Front Immunol"},{"key":"7080_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1146\/annurev-pathol-052016-100127","volume":"12","author":"JC Aster","year":"2017","unstructured":"Aster JC, Pear WS, Blacklow SC (2017) The Varied Roles of Notch in Cancer. Annu Rev Pathol 12:245\u2013275. https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100127","journal-title":"Annu Rev Pathol"},{"key":"7080_CR21","doi-asserted-by":"publisher","first-page":"609324","DOI":"10.3389\/fimmu.2020.609324","volume":"11","author":"M Garis","year":"2021","unstructured":"Garis M, Garrett-Sinha LA (2021) Notch signaling in B cell immune responses. Front Immunol 11:609324. Published 2021 Feb 5. https:\/\/doi.org\/10.3389\/fimmu.2020.609324","journal-title":"Front Immunol"},{"issue":"1","key":"7080_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-023-01439-z","volume":"16","author":"X Li","year":"2023","unstructured":"Li X, Yan X, Wang Y, Kaur B, Han H, Yu J (2023) The Notch signaling pathway: a potential target for cancer immunotherapy. J Hematol Oncol 16(1):45. Published 2023 May 2. https:\/\/doi.org\/10.1186\/s13045-023-01439-z","journal-title":"J Hematol Oncol"},{"issue":"Pt A","key":"7080_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ijbiomac.2022.09.203","volume":"222","author":"M Hashemi","year":"2022","unstructured":"Hashemi M, Hasani S, Hajimazdarany S et al (2022) Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance. Int J Biol Macromol 222(Pt A):1151\u20131167. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.09.203","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"7080_CR24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3324\/haematol.2023.282854","volume":"109","author":"BA Cardoso","year":"2024","unstructured":"Cardoso BA, Duque M, G\u00edrio A et al (2024) CASZ1 upregulates PI3K-AKT-mTOR signaling and promotes T-cell acute lymphoblastic leukemia. Haematologica 109(6):1713\u20131725. Published 2024 Jun 1. https:\/\/doi.org\/10.3324\/haematol.2023.282854","journal-title":"Haematologica"},{"issue":"11","key":"7080_CR25","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1172\/JCI34616","volume":"118","author":"A Silva","year":"2008","unstructured":"Silva A, Yunes JA, Cardoso BA et al (2008) PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118(11):3762\u20133774. https:\/\/doi.org\/10.1172\/JCI34616","journal-title":"J Clin Invest"},{"issue":"2","key":"7080_CR26","first-page":"99","volume":"14","author":"H Khoshamooz","year":"2020","unstructured":"Khoshamooz H, Kaviani S, Atashi A, Mirpour Hassankiadeh SH (2020) Combination Effect of Notch1 and PI3K\/AKT\/mTOR Signaling Pathways Inhibitors on T-ALL Cell Lines. Int J Hematol Oncol Stem Cell Res 14(2):99\u2013109","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"6","key":"7080_CR27","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24(6):1128\u20131138. https:\/\/doi.org\/10.1038\/leu.2010.69","journal-title":"Leukemia"},{"issue":"1","key":"7080_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-023-01929-1","volume":"23","author":"D Liang","year":"2024","unstructured":"Liang D, Wang Q, Zhang W et al (2024) JAK\/STAT in leukemia: a clinical update. Mol Cancer 23(1):25. Published 2024 Jan 26. https:\/\/doi.org\/10.1186\/s12943-023-01929-1","journal-title":"Mol Cancer"},{"issue":"2","key":"7080_CR29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.2019001417","volume":"136","author":"EJ Gang","year":"2020","unstructured":"Gang EJ, Kim HN, Hsieh YT et al (2020) Integrin \u03b16 mediates the chemotherapy resistance of acute lymphoblastic B-cell leukemia. Blood 136(2):210\u2013223. https:\/\/doi.org\/10.1182\/blood.2019001417","journal-title":"Blood"},{"issue":"1","key":"7080_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF (2020) The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. Cancer Discov 10(1):26\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0761","journal-title":"Cancer Discov"},{"issue":"5","key":"7080_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275\u2013287. https:\/\/doi.org\/10.1038\/nrc.2016.36","journal-title":"Nat Rev Cancer"},{"key":"7080_CR32","doi-asserted-by":"publisher","first-page":"101931","DOI":"10.1016\/j.ctrv.2019.101931","volume":"82","author":"J Veldman","year":"2020","unstructured":"Veldman J, Visser L, Berg AVD, Diepstra A (2020) Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma. Cancer Treat Rev 82:101931. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101931","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"7080_CR33","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2767-9764.CRC-23-0056","volume":"3","author":"CE Pillsbury","year":"2023","unstructured":"Pillsbury CE, Dougan J, Rabe JL et al (2023) Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. Cancer Res Commun 3(7):1248\u20131259. Published 2023 Jul 17. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0056","journal-title":"Cancer Res Commun"},{"key":"7080_CR34","doi-asserted-by":"publisher","first-page":"101952","DOI":"10.1016\/j.tranon.2024.101952","volume":"45","author":"L Lu","year":"2024","unstructured":"Lu L, Li J, Zheng Y et al (2024) High expression of SLC27A2 predicts unfavorable prognosis and promotes inhibitory immune infiltration in acute lymphoblastic leukemia. Transl Oncol 45:101952. https:\/\/doi.org\/10.1016\/j.tranon.2024.101952","journal-title":"Transl Oncol"},{"issue":"1","key":"7080_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","volume":"16","author":"M Li","year":"2023","unstructured":"Li M, Yang Y, Xiong L, Jiang P, Wang J, Li C (2023) Metabolism, metabolites, and macrophages in cancer. J Hematol Oncol 16(1):80. Published 2023 Jul 25. https:\/\/doi.org\/10.1186\/s13045-023-01478-6","journal-title":"J Hematol Oncol"},{"key":"7080_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","volume":"16","author":"IS Grewal","year":"1998","unstructured":"Grewal IS, Flavell RA (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16:111\u2013135. https:\/\/doi.org\/10.1146\/annurev.immunol.16.1.111","journal-title":"Annu Rev Immunol"},{"key":"7080_CR37","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","volume":"219","author":"T Tang","year":"2021","unstructured":"Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H (2021) Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint. Pharmacol Ther 219:107709. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107709","journal-title":"Pharmacol Ther"},{"issue":"6024","key":"7080_CR38","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP et al (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024):1612\u20131616. https:\/\/doi.org\/10.1126\/science.1198443","journal-title":"Science"},{"issue":"3","key":"7080_CR39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41590-023-01430-3","volume":"24","author":"PS Liu","year":"2023","unstructured":"Liu PS, Chen YT, Li X et al (2023) CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions. Nat Immunol 24(3):452\u2013462. https:\/\/doi.org\/10.1038\/s41590-023-01430-3","journal-title":"Nat Immunol"},{"key":"7080_CR40","doi-asserted-by":"publisher","first-page":"103520","DOI":"10.1016\/j.redox.2025.103520","volume":"80","author":"L Strohm","year":"2025","unstructured":"Strohm L, Ubbens H, Mihalikova D et al (2025) CD40-TRAF6 inhibition suppresses cardiovascular inflammation, oxidative stress and functional complications in a mouse model of arterial hypertension. Redox Biol 80:103520. https:\/\/doi.org\/10.1016\/j.redox.2025.103520","journal-title":"Redox Biol"},{"issue":"4","key":"7080_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-024-01045-1","volume":"119","author":"L Strohm","year":"2024","unstructured":"Strohm L, Daiber A, Ubbens H et al (2024) Role of inflammatory signaling pathways involving the CD40-CD40L-TRAF cascade in diabetes and hypertension-insights from animal and human studies. Basic Res Cardiol 119(4):1\u201318. https:\/\/doi.org\/10.1007\/s00395-024-01045-1","journal-title":"Basic Res Cardiol"},{"issue":"4","key":"7080_CR42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/2326-6066.CIR-17-0345","volume":"6","author":"JQ Zhang","year":"2018","unstructured":"Zhang JQ, Zeng S, Vitiello GA et al (2018) Macrophages and CD8\u2009+\u2009T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunol Res 6(4):434\u2013447. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0345","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"7080_CR43","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2326-6066.CIR-18-0061","volume":"7","author":"HS Ma","year":"2019","unstructured":"Ma HS, Poudel B, Torres ER et al (2019) A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity. Cancer Immunol Res 7(3):428\u2013442. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0061","journal-title":"Cancer Immunol Res"},{"key":"7080_CR44","doi-asserted-by":"publisher","first-page":"690869","DOI":"10.3389\/fimmu.2021.690869","volume":"12","author":"H Cai","year":"2021","unstructured":"Cai H, Zhang Y, Wang J, Gu J (2021) Defects in macrophage reprogramming in cancer therapy: the negative impact of PD-L1\/PD-1. Front Immunol 12:690869. Published 2021 Jun 23. https:\/\/doi.org\/10.3389\/fimmu.2021.690869","journal-title":"Front Immunol"},{"issue":"8","key":"7080_CR45","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.it.2021.06.001","volume":"42","author":"R Karki","year":"2021","unstructured":"Karki R, Kanneganti TD (2021) The \u2018cytokine storm\u2019: molecular mechanisms and therapeutic prospects. Trends Immunol 42(8):681\u2013705. https:\/\/doi.org\/10.1016\/j.it.2021.06.001","journal-title":"Trends Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07080-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07080-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:29Z","timestamp":1786785629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07080-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["7080"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07080-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PBMCs used in this study were obtained from Sun Yat-sen Memorial Hospital as anonymized leftover samples from healthy donors. Sample collection was approved by the ethics committee of Sun Yat-sen Memorial Hospital. All procedures were conducted in accordance with the Declaration of Helsinki and national regulations concerning research on human specimens.","order":1,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to the study, written informed consent was obtained from all donors (or their legal guardians) agreeing to use their samples for scientific research prior to this study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University (approval No. SYSU-IACUC-2025-002172). All applicable institutional and national guidelines for the care and use of animals were followed in this study.","order":3,"name":"Ethics","label":"Animal studies","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this is not a clinical trial.","order":4,"name":"Ethics","label":"Registry and the registration no. of the study\/trial","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this study did not involve human subjects.","order":5,"name":"Ethics","label":"Approval of the research protocol by an institutional reviewer board","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"355"}}